This chapter focuses on the impact of GLP-1 drugs on continuous glucose monitors (CGMs) and introduces the new platform called STELO, which aims to aid type two diabetes management and potentially help patients wean off these medications. The speakers also discuss the possibility of STELO being available without a prescription and at an affordable price point, potentially entering the consumer health gadget market.

Get the Snipd
podcast app

Unlock the knowledge in podcasts with the podcast player of the future.
App store bannerPlay store banner

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode

Save any
moment

Hear something you like? Tap your headphones to save it with AI-generated key takeaways

Share
& Export

Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more

AI-powered
podcast player

Listen to all your favourite podcasts with AI-powered features

Discover
highlights

Listen to the best highlights from the podcasts you love and dive into the full episode